Q&A with Larry Kadis, Federal Equipment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Larry Kadis, Federal Equipment
A Q&A with Larry Kadis, President and CEO of Federal Equipment, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 6, pp. 72

PharmTech:


Larry Kadis
How has the increasing focus on biopharmaceuticals affected your business?

Kadis:

Federal Equipment Company buys and sells used process and packaging equipment for the pharmaceutical industry—as the needs of the industry evolve, so will our inventory.

The challenge for Federal Equipment to serve biopharmaceutical manufacturers will be to identify equipment that has value on the secondary market. Many biopharmaceutical and protein process trains are specific to the product. For this equipment, we would need to find a company looking to manufacture that same product—this is not always easy. Equipment specifically designed to produce just one protein or product may not have much more value than scrap after its current owner is no longer using it. With that said, major pharmaceutical manufacturers are investing in biosimilar production facilities. This development fits well with Federal Equipment's business model. Historically, generic manufacturers and contract manufacturers have found a great deal of value in our inventory and services.

PharmTech:

Do you see a new industry trend emerging?

Kadis:

We currently see a strong trend towards containment equipment in solid-dose manufacturing driven by potent compound development. We have seen a great increase in the development of containment solutions for both pilot scale equipment as well as production scale equipment.

We also see a great opportunity for new solutions in aseptic manufacturing and fill–finish activities. These are very complex manufacturing processes and techniques and the manufacturers have made their way into headlines and news lately because of drug shortages. There are many new products and a great deal of life-saving products in vials—equipment suppliers should be leading the way with engineered solutions to the problems this segment of the industry currently faces.

In addition, we see manufacturers showing interest in disposable equipment for production processes. This will be an interesting study in whether a process with disposable equipment components will be more efficient, cost-effective, and reliable than a process with traditional equipment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here